Mainz Biomed B.v. Stock
Price
Target price
€0.23
€0.23
2.690%
0.006
2.690%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Mainz Biomed B.v. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Mainz Biomed B.v.
sharewise wants to provide you with the best news and tools for Mainz Biomed B.v., so we directly link to the best financial data sources.
Financials
News
EQS-News: Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
EQS-News: Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
EQS-News: Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
EQS-News: Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
EQS-News: Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
EQS-News: Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
EQS-News: Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
EQS-News: Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
EQS-News: Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
EQS-News: Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
EQS-News: Mainz Biomed Provides Half Year 2024 Corporate Update
EQS-News: Mainz Biomed Provides Half Year 2024 Corporate Update
EQS-News: Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
EQS-News: Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
EQS-News: Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
EQS-News: Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
EQS-News: Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
EQS-News: Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
EQS-News: Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQS-News: Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results
EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results